Get the Stockscreener App
3.39
0.88%
-0.03
After Hours:
3.40
0.010
+0.29%
Voyager Therapeutics Inc stock is traded at $3.39, with a volume of 305.49K.
It is down -0.88% in the last 24 hours and down -15.67% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$3.42
Open:
$3.45
24h Volume:
305.49K
Relative Volume:
0.58
Market Cap:
$188.48M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
5.2154
EPS:
0.65
Net Cash Flow:
$-28.66M
1W Performance:
-7.88%
1M Performance:
-15.67%
6M Performance:
-7.12%
1Y Performance:
-22.60%
1-Day Range:
$3.36
$3.555
1-Week Range:
$3.355
$3.91
52-Week Range:
$2.645
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.39 | 190.15M | 163.78M | 25.88M | -28.66M | 0.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Published on: 2026-02-14 07:15:36 - mfd.ru
Is Voyager Therapeutics Inc. stock a smart retirement pickJuly 2025 Weekly Recap & Consistent Profit Alerts - mfd.ru
What analyst consensus says on Voyager Therapeutics Inc. stockDividend Hike & Target Return Focused Picks - mfd.ru
Is Voyager Therapeutics Inc. subject to activist investor interestWeekly Investment Summary & Daily Chart Pattern Signals - mfd.ru
Voyager Therapeutics Announces Chief Medical Officer Resignation - TipRanks
Todd Alfred Carter Sells 3,525 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) COO Sells $17,590.65 in Stock - MarketBeat
Earnings Miss: Can Voyager Therapeutics Inc reach all time highs this year2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Alfred Sandrock Sells 12,192 Shares of Voyager Therapeutics (NASDAQ:VYGR) Stock - MarketBeat
What’s the MACD signal for Voyager Therapeutics Inc.2025 Pullback Review & Weekly High Potential Stock Alerts - mfd.ru
Voyager to Present at Upcoming Investor Conferences - markets.businessinsider.com
FY2030 Earnings Forecast for VYGR Issued By HC Wainwright - MarketBeat
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM) - The Globe and Mail
Can Voyager Therapeutics Inc. continue delivering strong returnsWeekly Stock Recap & Smart Money Movement Tracker - mfd.ru
Weekly Earnings: How does Voyager Therapeutics Inc compare to its peersPortfolio Update Report & Entry Point Confirmation Signals - baoquankhu1.vn
Voyager Therapeutics (NASDAQ:VYGR) Stock Crosses Below Fifty Day Moving AverageWhat's Next? - MarketBeat
Published on: 2026-01-27 16:25:36 - baoquankhu1.vn
Decliners Report: Can Voyager Therapeutics Inc reach all time highs this year - baoquankhu1.vn
Gene Therapy Market Outlook 2026-2031, Featuring Profiles - GlobeNewswire
Gene Therapy Market Outlook 2026-2031, Featuring Profiles of REGENXBIO, Oxford Biomedica, Voyager Therapeutics and More - Yahoo Finance
Stock Market Recap: How does Voyager Therapeutics Inc compare to its peers2025 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn
Inflation Data: Is Ferroglobe PLC forming a double bottom2025 Biggest Moves & High Return Trade Opportunity Guides - baoquankhu1.vn
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sentiment Recap: Is Voyager Therapeutics Inc stock a smart retirement pickMarket Volume Report & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Layoff Tracker: Takeda Slashes US Headcount, Hitting Neuro Commercial Teams Hard - BioSpace
Contrasting Voyager Therapeutics (NASDAQ:VYGR) and Alvotech (NASDAQ:ALVO) - Defense World
Risk Off: Should I buy Voyager Therapeutics Inc stock now2025 Trading Recap & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast - IT Business Net
Will Voyager Therapeutics Inc. stock see insider buyingSeasonal Picks & what to check before ordering - ulpravda.ru
How analysts rate Voyager Therapeutics Inc. stock todayWeekly Trend Recap & Expert Verified Movement Alerts - Улправда
Voyager Therapeutics, Inc. Highlights 2026 Milestones and Developments - TradingView — Track All Markets
Published on: 2026-01-08 10:47:34 - Улправда
VOYAGER THERAPEUTICS, INC. (VYGR) - MSN
Voyager Therapeutics (MEX:VYGR) EV-to-OCF : -1.62 (As of Dec. 31, 2025) - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
What analysts say about Voyager Therapeutics Inc stockGrowth Stock Opportunities & High Return Capital Gain - earlytimes.in
Growth Report: Why Voyager Therapeutics Inc. stock is recommended by analystsPortfolio Performance Report & Technical Pattern Based Buy Signals - Улправда
Why Voyager Therapeutics Inc. stock appeals to analystsEarnings Risk Summary & Fast Moving Trade Plans - Улправда
Voyager Therapeutics (NASDAQ:VYGR) Shares Cross Below Fifty Day Moving AverageTime to Sell? - MarketBeat
With Voyager Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
Why Voyager Therapeutics Inc. stock is recommended by analystsForecast Cut & Low Risk High Reward Ideas - Улправда
Rate Cut: Why Voyager Therapeutics Inc. stock is recommended by analysts2025 Technical Patterns & Growth Focused Entry Reports - Улправда
Is Voyager Therapeutics Inc. stock undervalued vs historical averagesChart Signals & Reliable Breakout Forecasts - Улправда
Movement Recap: Why Voyager Therapeutics Inc. stock is recommended by analystsJuly 2025 Action & AI Optimized Trade Strategies - Улправда
Voyager Throws 30 Staff Overboard After Novartis Sinks Two Programs - BioSpace
How Voyager Therapeutics Inc. stock reacts to oil pricesMarket Movement Recap & Reliable Intraday Trade Alerts - ulpravda.ru
Alzheimer's, ALS, And Huntington's Programs Keep Voyager Therapeutics On Investor Radar - RTTNews
Voyager Therapeutics Earnings Notes - Trefis
Voyager Therapeutics, Inc. $VYGR Shares Sold by Armistice Capital LLC - MarketBeat
Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage - Finviz
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):